India, Feb. 13 -- A six-month, all-oral treatment for multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) is more cost-effective and delivers better health outcomes than the longer regimens currently used in India, according to an economic evaluation published in the Indian Journal of Medical Research.

The study was conducted by the ICMR-National Institute for Research in Tuberculosis (ICMR-NIRT), assessed two bedaquiline-based regimens - BPaL (bedaquiline, pretomanid and linezolid) and BPaLM (with moxifloxacin) - against the existing bedaquiline-containing shorter (9-11 months) and longer (18-20 months) regimens implemented under the National TB Elimination Programme (NTEP), said the officials in a statement released o...